Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in ...